文献速递主动脉疾病

编辑精选——开窗或分支腔内修复复杂主动脉瘤患者抗血小板治疗的作用

Editor's Choice - Role of Antiplatelet Therapy in Patients Managed for Complex Aortic Aneurysms using Fenestrated or Branched Endovascular Repair.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2024-09-24

这项多中心回顾性分析纳入2018年1月1日至2022年12月31日接受开窗或分支腔内主动脉修复(F/B-EVAR)的1430例患者,比较术后单联抗血小板治疗(SAPT,955例)与双联抗血小板治疗(DAPT,475例)的30天及随访结局。DAPT组心血管缺血事件较低(SAPT 11.9% vs DAPT 8.2%;p=.040),36个月靶血管通畅率较高(SAPT 93.4% vs DAPT 97.0%;log rank p=.007),30天主要出血事件无差异。

要点

  • DAPT组30天心血管缺血事件低于SAPT组(11.9% vs 8.2%;p=.040)。
  • 36个月靶血管通畅率DAPT组高于SAPT组(93.4% vs 97.0%;log rank p=.007)。
  • 30天主要出血事件两组无差异(SAPT 7.5% vs DAPT 6.3%;p=.40)。

核心结论

  • F/B-EVAR术后DAPT与较低的心血管缺血事件风险和较高的靶血管通畅率相关,尤其在B-EVAR病例中。
  • 30天主要出血事件未见差异。

研究设计与样本

  • 多中心回顾性分析,纳入2018年1月1日至2022年12月31日期间管理的F/B-EVAR患者。
  • 共纳入1430例患者,分为SAPT组(955例,阿司匹林或氯吡格雷)和DAPT组(475例,阿司匹林联合氯吡格雷)。
  • SAPT或DAPT持续时间为1至6个月。
  • 主要结局为30天死亡、心血管缺血事件和主要出血事件;次要结局为随访期间生存率和靶血管通畅率。

主要发现

  • 30天死亡率两组相似(SAPT 2.1% vs DAPT 1.5%;p=.42)。
  • 心血管缺血事件DAPT组较低(SAPT 11.9% vs DAPT 8.2%;p=.040),DAPT是急性肠系膜缺血(p=.009)和下肢缺血(p=.020)的独立保护因素。
  • 30天主要出血事件两组无差异(SAPT 7.5% vs DAPT 6.3%;p=.40)。
  • 平均随访21.8±2.9个月,Cox回归显示无生存混杂因素,两组生存率相似(log rank p=.71)。
  • 36个月靶血管通畅率DAPT组较高(SAPT 93.4%,标准误0.7% vs DAPT 97.0%,标准误0.6%;log rank p=.007);Cox回归显示B-EVAR是靶血管通畅率较差的预测因素(风险比2.03,95%置信区间1.36-3.03;p<.001);在B-EVAR患者中DAPT与较高通畅率相关(SAPT 87.2%,标准误2.1% vs DAPT 94.9%,标准误1.9%;p<.001)。

关键数值与推荐

  • DAPT组30天心血管缺血事件8.2%,SAPT组11.9%(p=.040)。
  • DAPT组36个月靶血管通畅率97.0%(标准误0.6%),SAPT组93.4%(标准误0.7%)(log rank p=.007)。
  • B-EVAR患者中DAPT组靶血管通畅率94.9%(标准误1.9%),SAPT组87.2%(标准误2.1%)(p<.001)。
  • 30天主要出血事件DAPT组6.3%,SAPT组7.5%(p=.40)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Despite the increasing number of fenestrated and branched endovascular aortic repair (F/B-EVAR) procedures, evidence on post-operative antiplatelet therapy is very limited. This study aimed to investigate the role of single antiplatelet therapy (SAPT) vs. double antiplatelet therapy (DAPT) after F/B-EVAR in 30 day and follow up outcomes. METHODS: A multicentre retrospective analysis was conducted, including F/B-EVAR patients managed from 1 January 2018 to 31 December 2022. Comparative outcomes were assessed according to post-operative antiplatelet therapy. The cohort was divided into the SAPT group (acetylsalicylic acid [ASA] or clopidogrel) and DAPT group (ASA and clopidogrel). The duration of SAPT or DAPT was one to six months. Primary outcomes were 30 day death, and cardiovascular ischaemic and major haemorrhagic events. Secondary outcomes were survival and target vessel (TV) patency during follow up. RESULTS: A total of 1 430 patients were included: 955 under SAPT and 475 under DAPT. The 30 day mortality rate was similar (SAPT 2.1% vs. DAPT 1.5%; p = .42). Cardiovascular ischaemic events were lower in the DAPT group (SAPT 11.9% vs. DAPT 8.2%; p = .040), with DAPT being an independent protector for acute mesenteric (p = .009) and lower limb ischaemia (p = .020). No difference was found in 30 day major haemorrhagic events (SAPT 7.5% vs. DAPT 6.3%; p = .40). The mean follow up was 21.8 ± 2.9 months. Cox regression showed no survival confounders, with similar rates between groups (log rank p = .71). DAPT patients enjoyed higher TV patency (SAPT 93.4%, standard error [SE] 0.7% vs. DAPT 97.0%, SE 0.6%; log rank p = .007) at thirty six months. Cox regression revealed B-EVAR as a predictor of worse TV patency (hazard ratio 2.03, 95% confidence interval 1.36 - 3.03; p < .001). DAPT was related to higher patency within B-EVAR patients (SAPT 87.2%, SE 2.1% vs. DAPT 94.9%, SE 1.9%; p < .001). CONCLUSION: DAPT after F/B-EVAR was associated with lower risk of cardiovascular ischaemic events and higher TV patency, especially in B-EVAR cases. No difference in major haemorrhagic events was observed at 30 days.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Nana P, Spanos K, Tsilimparis N, et al. Editor's Choice - Role of Antiplatelet Therapy in Patients Managed for Complex Aortic Aneurysms using Fenestrated or Branched Endovascular Repair. Eur J Vasc Endovasc Surg. 2024. PMID: 39321954. doi:10.1016/j.ejvs.2024.09.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。